[HTML] sciencedirect.com

[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …

YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu… - Annals of oncology, 2015 - Elsevier
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
被引用次数：777 相关文章
[PDF] researchgate.net

[PDF][PDF] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …

YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu… - 2015 - researchgate.net
original article Page 1 First-line erlotinib versus gemcitabine/cisplatin in patients with
advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu… - Annals of oncology …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu, X Liu… - Annals of …, 2015 - annalsofoncology.org
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu, X Liu… - Annals of …, 2015 - eprints.um.edu.my
Background: The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu, X Liu… - Annals of oncology …, 2015 - mymedr.afpm.org.my
BACKGROUND: The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu, X Liu… - Annals of Oncology …, 2015 - europepmc.org
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

[引用][C] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …

YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong… - Annals of …, 2015 - cir.nii.ac.jp
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive
non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE …

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized …

YL Wu, C Zhou, CK Liam, G Wu, X Liu… - Annals of …, 2015 - eprints.um.edu.my
Background: The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …